← Back to Search

Radiation Therapy

V/Q SPECT for Non-Small Cell Lung Cancer

N/A
Waitlist Available
Led By Shruti Jolly, M.D.
Research Sponsored by University of Michigan Rogel Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 60 months
Awards & highlights

Study Summary

This trial is designed to see if using a PET scan and a perfusion scan before and during radiation therapy for lung cancer helps to predict how well the treatment works and how well the lung functions during treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 60 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 60 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Comparison of delivered dose to dose that would have been administered using the criteria described in protocol UMCC 2007.123 (NCT01190527)
The number of patients for whom treatment is feasible.
The number of patients that experience grade 2 or greater esophageal toxicity
+1 more
Secondary outcome measures
Overall survival time
Time to local progression

Trial Design

1Treatment groups
Experimental Treatment
Group I: Response-driven Adaptive RTExperimental Treatment6 Interventions
Patients will receive treatment 5 days per week, in once daily fractions, for 30 treatments with dose per fraction individually adapted over the final 9 treatments. Patients may also receive concurrent chemotherapy with Carboplatin and Paclitaxel. Patients may receive consolidation chemotherapy (carboplatin and paclitaxel) or immunotherapy (durvalumab) at the discretion of the medical oncologist.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
FDG-PET
2008
Completed Phase 4
~600
Paclitaxel
2011
Completed Phase 4
~5380
V/Q SPECT
2016
N/A
~50
Durvalumab
2017
Completed Phase 2
~3870
Response-driven Adaptive Radiation Therapy
2016
N/A
~50
Carboplatin
2014
Completed Phase 3
~6670

Find a Location

Who is running the clinical trial?

University of Michigan Rogel Cancer CenterLead Sponsor
294 Previous Clinical Trials
24,222 Total Patients Enrolled
Shruti Jolly, M.D.Principal InvestigatorUniversity of Michigan Rogel Cancer Center
3 Previous Clinical Trials
190 Total Patients Enrolled
~5 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top